Data from University of Texas, Health Science Center advance knowledge in cancer vaccines

Investigators publish new data in the report "Management of high risk metastatic prostate cancer: the case for novel therapies. We reviewed the results of preliminary studies of select novel agents for metastatic prostate cancer and discuss the potential benefit of these agents for earlier stage disease, eg biochemically recurrent prostate cancer with high risk features. Available data on select investigational immunotherapies as well as endothelin-A receptor antagonists and survivin inhibitors were obtained and reviewed through PubMed searches, conference proceedings and unpublished proprietary information, when available. A large number of promising agents are in varying stages of...

Want to see the full article?

• Purchase this article for only $3.00